Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,744 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy.
Lustig G, Cele S, Karim F, Derache A, Ngoepe A, Khan K, Gosnell BI, Moosa MS, Ntshuba N, Marais S, Jeena PM, Govender K, Adamson J, Kløverpris H, Gupta RK, Harrichandparsad R, Patel VB, Sigal A. Lustig G, et al. Among authors: gupta rk. PLoS Pathog. 2021 Sep 23;17(9):e1009871. doi: 10.1371/journal.ppat.1009871. eCollection 2021 Sep. PLoS Pathog. 2021. PMID: 34555123 Free PMC article.
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ, Lockman S, Pillay D, de Oliveira T, Clumeck N, Hunt G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK. Gregson J, et al. Among authors: gupta rk. Lancet Infect Dis. 2017 Mar;17(3):296-304. doi: 10.1016/S1473-3099(16)30469-8. Epub 2016 Dec 1. Lancet Infect Dis. 2017. PMID: 27914856 Free PMC article.
Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
Collier D, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group. Collier D, et al. Among authors: gupta rk. Clin Infect Dis. 2017 Apr 15;64(8):1006-1016. doi: 10.1093/cid/cix015. Clin Infect Dis. 2017. PMID: 28329393 Free PMC article.
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P, Watera C, Aghokeng A, Mutenda N, Dzangare J, Hone S, Hang ZZ, Garcia J, Garcia Z, Marchorro P, Beteta E, Giron A, Hamers R, Inzaule S, Frenkel LM, Chung MH, de Oliveira T, Pillay D, Naidoo K, Kharsany A, Kugathasan R, Cutino T, Hunt G, Avila Rios S, Doherty M, Jordan MR, Bertagnolio S. Gupta RK, et al. Lancet Infect Dis. 2018 Mar;18(3):346-355. doi: 10.1016/S1473-3099(17)30702-8. Epub 2017 Dec 5. Lancet Infect Dis. 2018. PMID: 29198909 Free PMC article.
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
Derache A, Iwuji CC, Danaviah S, Giandhari J, Marcelin AG, Calvez V, de Oliveira T, Dabis F, Pillay D, Gupta RK. Derache A, et al. Among authors: gupta rk. J Antimicrob Chemother. 2019 Feb 1;74(2):473-479. doi: 10.1093/jac/dky428. J Antimicrob Chemother. 2019. PMID: 30380053 Free PMC article. Clinical Trial.
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S. Phillips AN, et al. Among authors: gupta rk. Lancet HIV. 2020 Mar;7(3):e193-e200. doi: 10.1016/S2352-3018(19)30400-X. Epub 2020 Feb 5. Lancet HIV. 2020. PMID: 32035041 Free PMC article.
Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
El Bouzidi K, Datir RP, Kwaghe V, Roy S, Frampton D, Breuer J, Ogbanufe O, Murtala-Ibrahim F, Charurat M, Dakum P, Sabin CA, Ndembi N, Gupta RK. El Bouzidi K, et al. Among authors: gupta rk. J Antimicrob Chemother. 2022 Feb 2;77(2):474-482. doi: 10.1093/jac/dkab385. J Antimicrob Chemother. 2022. PMID: 34741609 Free PMC article.
2,744 results